We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fresenius Medical Care AG & Co. KGaA (FMS) - free report >>
Ocular Therapeutix, Inc. (OCUL) - free report >>
Bassett Furniture Industries, Incorporated (BSET) - free report >>
Image: Shutterstock
New Strong Sell Stocks for October 14th
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
Arconic Corporation is a provider of aluminum sheet, plate and extrusions, as well as architectural products to transportation, aerospace, industrial, packaging and building and construction markets. The Zacks Consensus Estimate for its current year earnings has been revised 2.6% downward over the last 30 days.
Bassett Furniture Industries, Incorporated (BSET - Free Report) is a manufacturer and marketer of high quality, mid-priced home furnishings. The Zacks Consensus Estimate for its current year earnings has been revised 1.1% downward over the last 30 days.
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) is a provider of dialysis care and related services. The Zacks Consensus Estimate for its current year earnings has been revised 0.5% downward over the last 30 days.
Ocular Therapeutix, Inc. (OCUL - Free Report) is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Zacks Consensus Estimate for its current year earnings has been revised 18.6% downward over the last 30 days.
Protagonist Therapeutics, Inc. (PTGX - Free Report) is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Zacks Consensus Estimate for its current year earnings has been revised nearly 0.4% downward over the last 30 days.
View the entire Zacks Rank #5 List.